Saudi Food and Drug Authority - Regulatory authority for pharmaceuticals and medical devices in Saudi Arabia
显示 2023 年的审批记录
仅限当前页。暂不支持搜索完整审批数据集。
药物名称 | 公司 | 适应症 | 日期 | 类型 |
|---|---|---|---|---|
| Fetazim | Pharma International Co. | powder for solution for injection | Jan 1, 2023 | Generic |
| Pantrox | Hetero Labs Limited Unit – V | Gastro-resistant tablet | Jan 1, 2023 | Generic |
| Sulbus 60 mg per 10 ml | INTAS PHARMACEUTICALS LIMITED | Concentrate for solution for infusion | Jan 1, 2023 | Generic |
| Pantrox | Hetero Labs Limited Unit – V | Gastro-resistant tablet | Jan 1, 2023 | Generic |
| Movicol Paediatric Plain | NORGINE LIMITED | Powder for oral solution | Jan 1, 2023 | NCE |
| Docetaxel AqVida 80 mg per 4 ml | AqVida GmbH Dassow | Solution for infusion | Jan 1, 2023 | Generic |
| Triplixam | SERVIER | Film-coated tablet | Jan 1, 2023 | NCE |
| Fetazim | Pharma International Co. | powder for solution for injection | Jan 1, 2023 | Generic |
| Pantrox | Hetero Labs Limited Unit – V | Gastro-resistant tablet | Jan 1, 2023 | Generic |
| Docetaxel AqVida 20 mg per 1 ml | AqVida GmbH Dassow | Solution for infusion | Jan 1, 2023 | Generic |
| Pelgraz 6 mg in 0.6 ml | INTAS PHARMACEUTICALS LIMITED | Solution for injection in pre-filled syringe | Jan 1, 2023 | Biological |
| Lomipat | Hetero Labs Limited Unit – V | Tablet | Jan 1, 2023 | Generic |
| Lomipat | Hetero Labs Limited Unit – V | Tablet | Jan 1, 2023 | Generic |
| Docetaxel AqVida 160 mg per 8 ml | AqVida GmbH Dassow | Solution for infusion | Jan 1, 2023 | Generic |
| Evoltra | PHARMACHEMIE | Concentrate for solution for infusion | Jan 1, 2023 | NCE |
| Lomipat | Hetero Labs Limited Unit – V | Tablet | Jan 1, 2023 | Generic |
| Elfonis 400 mg per 250 ml | Hemomont | Solution for infusion | Jan 1, 2023 | Generic |
| Clodipan 16 mg and 5 mg | ADAMED Pharma S.A | Capsule, hard | Jan 1, 2023 | NCE |
| Welireg | MSD INTERNATIONAL GMBH | Film-coated tablet | Jan 1, 2023 | NCE |
| Byannli | JANSSEN PHARMACEUTICA N.V. | Prolonged-release suspension for injection | Jan 1, 2023 | NCE |
